Table 1.
Relationship between the expression level of TGFB1 and clinical characteristics in ES.
| Characteristic | Low expression of TGFBI | High expression of TGFBI | p |
|---|---|---|---|
| n | 50 | 51 | |
| Metastasis, n (%) | 0.686 | ||
| No | 39 (38.6%) | 37 (36.6%) | |
| Yes | 11 (10.9%) | 14 (13.9%) | |
| Tumor region, n (%) | 1.000 | ||
| Distal | 18 (28.1%) | 18 (28.1%) | |
| Other | 2 (3.1%) | 1 (1.6%) | |
| Proximal | 12 (18.8%) | 13 (20.3%) | |
| Proximal and distal | 0 (0%) | 0 (0%) | |
| Age, n (%) | 1.000 | ||
| <18 | 39 (38.6%) | 39 (38.6%) | |
| ≥18 | 11 (10.9%) | 12 (11.9%) | |
| Gender, n (%) | 0.372 | ||
| Female | 23 (22.8%) | 18 (17.8%) | |
| Male | 27 (26.7%) | 33 (32.7%) | |
| Race, n (%) | |||
| American Indian or Alaska Native | 0 (0%) | 1 (1.3%) | |
| Asian | 3 (3.9%) | 4 (5.3%) | |
| Black or African American | 5 (6.6%) | 5 (6.6%) | |
| Native Hawaiian or other Pacific Islander | 0 (0%) | 0 (0%) | |
| White | 28 (36.8%) | 30 (39.5%) | |
| Age, median (IQR) | 15.27 (12.35, 17.69) | 15.06 (12.63, 17.77) | 0.989 |